FP14.11 Icotinib versus Chemotherapy as Adjuvant Treatment for Stage II–IIIA EGFR-Mutant NSCLC (EVIDENCE): A Randomized, Open-Label, Phase 3 StudyCaicun Zhou, Li Mao, Shidong Xu et al.|Journal of Thoracic Oncology|2021Cited by 5
P78.03 Camrelizumab Umbrella Trial Based on PD-L1 Expression: OS and PFS2 in Pre-Treated Advanced NSCLCCheng Huang, Xiuquan Lin, Yi‐Long Wu et al.|Journal of Thoracic Oncology|2021Cited by 0